| Literature DB >> 27272256 |
Shujun Liu1, Qiaoyan Guo1, Hongbo Han2, Peihe Cui1, Xiao Liu1, Lining Miao1, Hongbin Zou1, Guangdong Sun3.
Abstract
OBJECTIVE: To investigate the clinical and histopathological features of non-diabetic renal disease (NDRD) superimposed on diabetic nephropathy (DN) in northeastern Chinese patients with type 2 diabetes mellitus (T2D), and compare the changes with those of pure DN and isolated NDRD.Entities:
Keywords: Clinical manifestations; Diabetic nephropathy; Histopathology; Non-diabetic renal disease; Renal biopsy; Type 2 diabetes
Mesh:
Year: 2016 PMID: 27272256 PMCID: PMC5031732 DOI: 10.1007/s11255-016-1331-y
Source DB: PubMed Journal: Int Urol Nephrol ISSN: 0301-1623 Impact factor: 2.370
Fig. 1Number of type 2 diabetic patients who underwent renal biopsy between 2000 and 2015. DN diabetic nephropathy, NDRD non-diabetic renal disease, DN + NDRD NDRD superimposed on DN
Baseline characteristics of 273 type 2 diabetic patients at the time of renal biopsy
| Variables | Results |
|---|---|
| Age at biopsy (years) mean ± SD (range) | 51.1 ± 12.4 (22–82) |
| Sex (male/female) | (172/101) |
| Duration of DM (months) | 52.0 ± 68.9 (1–487) |
| Insulin treatment (yes, %) | 110 (40.3 %) |
| Diabetic retinopathy (yes, %) | 37 (13.6 %) |
| Nephrotic syndrome (yes, %) | 77 (28.2 %) |
| Renal failure (yes, %) | 42 (15.4 %) |
| Hypertension (yes, %) | 115 (42.1 %) |
| Dyslipidemia (yes, %) | 188 (68.9 %) |
| RAAS blockade therapy (yes, %) | 113 (41.4 %) |
| Body mass index (kg/m2) | 25.9 ± 4.1 (16–41.1) |
| 24 h-urinary protein (g) | 4.81 ± 4.16 (0.3–28.2) |
| Proteinuria (%) | 261 (95.6 %) |
| Hematuria (%) | 188 (68.9 %) |
|
| |
| Diabetic nephropathy (DN) | 68 (24.9 %) |
| Non-diabetic renal disease (NDRD) | 175 (64.1 %) |
| NDRD superimposed on DN | 30 (11.0 %) |
NDRD non-diabetic renal disease, DN diabetic nephropathy, DN + NDRD NDRD superimposed on DN, RAAS renin–angiotensin–aldosterone system, SD standard deviation
Pathological diagnosis of NDRD, with or without DN in type 2 diabetic patients
| Pathologic diagnosis based on renal biopsy | NDRD ( | DN + NDRD ( | Total ( |
|---|---|---|---|
| Membranous nephropathy | 52 (29.7) | 6 (20) | 58 (28.3) |
| IgA nephropathy | 40 (22.9) | 1 (3.3) | 41 (20) |
| Mesangioproliferative glomerulonephritis (MPGN) | 14 (8.0) | 0 | 14 (6.8) |
| Minimal change disease | 6 (3.4) | 0 | 6 (2.9) |
| Crescentic glomerulonephritis | 4 (2.3) | 0 | 4 (2.0) |
| Focal segmental glomerulosclerosis | 3 (1.7) | 0 | 3 (1.5) |
| Interstitial nephritis | 10 (5.7) | 1 (3.3) | 11 (5.4) |
| Lupus nephritis | 9 (5.1) | 0 | 9 (4.4) |
| HBV-associated glomerulonephritis | 8 (4.6) | 0 | 8 (3.9) |
| Hypertensive renal arteriolar sclerosis | 6 (3.4) | 19 (63.3) | 25 (12.2) |
| ANCA-associated vasculitis | 5 (2.9) | 1 (3.3) | 6 (2.9) |
| Thrombotic microangiopathy (TMA) | 4 (2.3) | 2 (6.7) | 6 (2.9) |
| Amyloidosis | 4 (2.3) | 0 | 4 (2.0) |
| Henoch-Schonlein purpura | 1 (0.6) | 0 | 1 (0.5) |
| Lipoprotein glomerulopathy | 1 (0.6) | 0 | 1 (0.5) |
| Acute tubular necrosis | 1 (0.6) | 0 | 1 (0.5) |
| Others | 7 (3.9) | 0 | 7 (3.3) |
NDRD non-diabetic renal disease, DN diabetic nephropathy, DN + NDRD NDRD superimposed on DN, IgA Immunoglobulin A, HBV hepatitis B virus, ANCA anti-neutrophil cytoplasmic antibody
Comparison of demographic, clinical characteristics, and laboratory data of diabetic patients by study group (N = 273)
| Parameters | DN ( | NDRD ( | DN + NDRD ( |
|---|---|---|---|
| Age at biopsy (years) | 50.8 ± 10.3 | 50.6 ± 12.9 | 54.9 ± 13.4 |
| Sex (male/female) | 44/24 | 111/64 | 17/13 |
| Duration of DM (months) | 87.1 ± 73.2 (1–243.3) | 32.7 ± 52.1 (1–396)* | 89.3 ± 98.6 (1–486.6)& |
| <12 months | 13 (19.1 %) | 88 (50.3 %) | 5 (16.7 %) |
| 12–60 months | 17 (25 %) | 50 (28.6 %) | 7 (23.3 %) |
| 61–120 months | 11 (16.2 %) | 23 (13.1 %) | 8 (26.7 %) |
| >120 months | 27 (39.7 %) | 14 (8.0 %) | 10 (33.3 %) |
| Insulin treatment (yes, %) | 35 (51.5 %) | 55 (31.4 %) | 20 (66.7 %) |
| Diabetic retinopathy (yes, %) | 18 (26.5 %) | 12 (6.9 %) | 7 (23.3 %) |
| Proteinuria (yes, %) | 66 (97.1 %) | 165 (94.3 %) | 30 (100 %) |
| Hematuria (yes, %) | 51 (80.9 %) | 116 (66.3 %) | 21 (70.0 %) |
| Body mass index (kg/m2) | 25.2 ± 3.2 (17.3–33.3) | 26.2 ± 4.4 (16–41.1) | 25.9 ± 3.5 (19.5–33.0) |
| <18 | 2 (2.9 %) | 5 (2.9 %) | 0 (0.0 %) |
| 18–25 | 30 (44.1 %) | 60 (34.3 %) | 8 (26.7 %) |
| >25 | 36 (53.0 %) | 110 (62.8 %) | 22 (73.3 %) |
| eGFR at Biopsy (mL/min/1.73 m2) | 55.7 ± 3.3 | 74.9 ± 3.0* | 61.1 ± 6.9 |
| Renal failure (yes, %) | 29 (42.6 %) | 49 (28.0 %)* | 13 (43.3 %) |
| Dyslipidemia (yes, %) | 49 (72.1 %) | 118 (67.4 %) | 21 (70.0 %) |
| Hypertension (yes, %) | 40 (58.8 %) | 45 (25.7 %) | 30 (100 %) |
| Systolic BP (mmHg) | 153 ± 22 (120–230) | 137 ± 19 (100–230)* | 153 ± 20 (120–220)& |
| Diastolic BP (mmHg) | 88 ± 11 (70–120) | 87 ± 13 (60–150) | 91 ± 12 (60–118) |
| Kidney long axis (cm) | 10.9 ± 1.0 (9.4–13.8) | 10.8 ± 0.9 (9.0–13.4) | 10.9 ± 0.8 (9.7–12.9) |
| Laboratory findings | |||
| Hemoglobin (g/L) | 117 ± 22 (71–172) | 133 ± 29 (30–186)* | 120 ± 25 (58–174)& |
| Serum creatinine (μmol/L) | 149.8 ± 159.2 (46.2–1154.3) | 139.0 ± 158.4 (26.0–1202.2) | 137.1 ± 93.0 (44.0–395.2) |
| Serum albumin (g/L) | 30.8 ± 7.8 (15.3–51.9) | 32.7 ± 9.0 (13.1–49.1) | 31.6 ± 9.2 (20.0–51.6) |
| Total cholesterol (mmol/L) | 6.6 ± 1.8 (3.4–13.1) | 6.9 ± 3.1 (1.8–20.1) | 7.1 ± 2.8 (3.2–15.0) |
| HbA1c (%) | 7.4 ± 2.4 (4.4–17.7) | 6.9 ± 1.9 (4.6–16.2) | 6.7 ± 1.3 (3.8–9.7) |
| Proteinuria (g/d) | 5.26 ± 3.60 (0.15–19) | 4.41 ± 4.33 (0.13–28.2) | 6.12 ± 4.12 (0.35–15.62) |
DN diabetic nephropathy, NDRD non-diabetic renal disease, DN + NDRD NDRD superimposed on DN, HbA1c glycated hemoglobin
* P < 0.05 for comparison of NDRD versus DN subgroups & P < 0.05 for comparison of DN + NDRD versus NDRD subgroups
Reported indicators and significant laboratory values in diabetic patients undergoing renal biopsy
| Variables | DN ( | NDRD ( | DN + NDRD ( |
|---|---|---|---|
| Proteinuria (g/day) | |||
| | 1 (1.5) | 3 (1.7) | 0 (0) |
| <0.5 | 1 (1.5) | 17 (9.7) | 2 (6.7) |
| 0.5–3.5 | 23 (33.8) | 81 (46.3) | 6 (20.0) |
| >3.5 | 43 (63.2) | 74 (42.3) | 22 (73.3) |
| Hematuria | |||
| | 3 (4.4) | 1 (0.6) | 1 (3.3) |
| Urine RBC > 3/HPF | 51 (75) | 117 (66.9) | 21 (70) |
| Urine RBC > 10/HPF | 21 (30.9) | 61 (34.9) | 11 (36.7) |
| Urine RBC > 20/HPF | 10 (14.7) | 48 (27.4) | 7 (10.3) |
| Serum creatinine (μmol/L) | |||
| | 0 (0.0) | 1 (0.6) | 0 (0.0) |
| <178 | 57 (83.9) | 148 (84.5) | 25 (83.3) |
| ≥178 | 11 (16.1) | 26 (14.9) | 5 (16.7) |
| Any positive serologic test | |||
| (+) HBsAg or HCV antibody | 18 (26.5) | 32 (18.3) | 5 (16.7) |
| (+) HIV | 0 (0.0) | 0 (0.0) | 0 (0.0) |
DN diabetic nephropathy, NDRD non-diabetic renal disease, DN + NDRD NDRD superimposed on DN, HPF high-power field, HBsAg hepatitis B surface antigen, HCV hepatitis C virus, HIV human immunodeficiency virus